Clinical Report: Upcoming Clinical Trial to Evaluate Two Therapeutics for Ebola
Overview
A clinical trial will assess the efficacy of remdesivir and MBP-134 against the Bundibugyo ebolavirus in the DRC.
Background
The Bundibugyo ebolavirus outbreak in Central Africa is the third largest on record, with nearly 1,100 confirmed cases and over 275 deaths reported. There are currently no proven drugs or vaccines for this species of Ebola.
Data Highlights
No numerical data available in the source material.
Key Findings
The clinical trial will test remdesivir and MBP-134 for efficacy against Bundibugyo ebolavirus.
Nearly 1,100 cases and over 275 deaths have been reported in the DRC as of this week.
The trial will require approximately 1,000 participants due to the lower case fatality rate of the Bundibugyo species.
Only therapeutic use of MBP-134 will be tested in this trial.
The trial is supported by the U.S. government through BARDA, which has supplied doses of MBP-134.
Clinical Implications
The trial currently lacks proven therapeutic options for Bundibugyo ebolavirus.
Conclusion
The upcoming clinical trial will test the efficacy of remdesivir and MBP-134 against the Bundibugyo ebolavirus.
